Satisfaction With Phosphodiesterase 5 Inhibitors Treatment In Patients With Cardiovascular Risk (TIERRA)

This study has been completed.
Information provided by (Responsible Party):
Pfizer Identifier:
First received: April 1, 2009
Last updated: February 12, 2013
Last verified: February 2013

Evaluate satisfaction in people treated with IPDE5 inhibitors over time

Condition Phase
Erectile Dysfunction
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Satisfaction With Treatment In Patients With Erectile Dysfunction And Cardiovascular Risk And/Or Previous Cardiovascular Event.

Resource links provided by NLM:

Further study details as provided by Pfizer:

Primary Outcome Measures:
  • EDITS [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • SEAR [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Medication prescribed [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 720
Study Start Date: December 2007
Study Completion Date: May 2008
Primary Completion Date: May 2008 (Final data collection date for primary outcome measure)
filling in questionnaires

Detailed Description:

12 first patients that are eligible


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

People with cv risk


Inclusion Criteria:

  • CV risk factors
  • Male above 18

Exclusion Criteria:

  • Non-informed consent
  Contacts and Locations
Please refer to this study by its identifier: NCT00874185

Sponsors and Collaborators
Study Director: Pfizer Call Center Pfizer
  More Information

Additional Information:
No publications provided

Responsible Party: Pfizer Identifier: NCT00874185     History of Changes
Other Study ID Numbers: A1481256, A1481256
Study First Received: April 1, 2009
Last Updated: February 12, 2013
Health Authority: Spain: Ethics Committee

Keywords provided by Pfizer:

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Sexual and Gender Disorders
Mental Disorders
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions processed this record on April 22, 2014